{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:37:55Z","timestamp":1793147875537,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.annonc.2026.10.1288","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:55:04Z","timestamp":1792756504000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+\/HER2\u2013 early breast cancer: Six-year follow-up of the NATALEE trial"],"prefix":"10.1016","author":[{"given":"D.J.","family":"Slamon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.N.","family":"Hortobagyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Stroyakovskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Yardley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-S.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Crown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-A.","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Hurvitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.H.","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Cuesta","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Untch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Visco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Peyrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Taran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.annonc.2026.10.1288_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.annonc.2026.10.1288_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2026.10.1288_bib3","article-title":"Short-term risk of recurrence in patients (pts) with HR+\/HER2\u2212 early breast cancer (EBC) treated with endocrine therapy (ET) in randomized clinical trials (RCTs): A meta-analysis","volume":"42","author":"Curigliano","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2026.10.1288_bib4","article-title":"235P Long-term risk of recurrence (RoR) among real-world patients (pts) with hormone receptor\u2013positive (HR+)\/HER2-negative (HER2\u2013) early breast cancer (EBC) with N1 disease","volume":"11","author":"Jhaveri","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.annonc.2026.10.1288_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104437","article-title":"Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+\/HER2- early breast cancer","volume":"81","author":"O'Shaughnessy","year":"2025","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.annonc.2026.10.1288_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2026.10.1288_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djag201","article-title":"Recurrence risk in HR-positive\/HER2-negative early breast cancer: real-world US electronic health records study","author":"Tarantino","year":"2026","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"10.1016\/j.annonc.2026.10.1288_bib8","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2026.10.1288_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.106021","article-title":"Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data","volume":"11","author":"Tolaney","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.annonc.2026.10.1288_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.breast.2021.02.009","article-title":"Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis","volume":"57","author":"Salvo","year":"2021","journal-title":"Breast"},{"issue":"12","key":"10.1016\/j.annonc.2026.10.1288_bib11","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2026.10.1288_bib12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.annonc.2025.10.005","article-title":"Overall survival with abemaciclib in early breast cancer","volume":"37","author":"Johnston","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.1288_bib13","unstructured":"Food and Drug Administration. FDA approves ribociclib with an aromatase inhibitor and ribociclib and letrozole co-pack for early high-risk breast cancer. 2026."},{"key":"10.1016\/j.annonc.2026.10.1288_bib14","unstructured":"European Medicines Agency. Kisqali: EPAR \u2013 Assessment report \u2013 Variation.; 2024."},{"issue":"11","key":"10.1016\/j.annonc.2026.10.1288_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105858","article-title":"Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive\/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival","volume":"10","author":"Crown","year":"2025","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.annonc.2026.10.1288_bib16","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1001\/jamaoncol.2025.3700","article-title":"Ribociclib plus endocrine therapy in hormone receptor-positive\/ERBB2-negative early breast cancer: 4-year outcomes from the NATALEE randomized clinical trial","volume":"11","author":"Fasching","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2026.10.1288_bib17","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-026-02352-2","article-title":"Safety and treatment duration of ribociclib + nonsteroidal aromatase inhibitor in HR+\/HER2\u2212 early breast cancer: a phase 3 randomized controlled trial (NATALEE)","author":"Rugo","year":"2026","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.annonc.2026.10.1288_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231178125","article-title":"Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+\/HER2- early breast cancer","volume":"15","author":"Slamon","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.10.1288_bib19","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"24","key":"10.1016\/j.annonc.2026.10.1288_bib20","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1200\/JCO.20.03613","article-title":"Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.10.1288_bib21","unstructured":"A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+\/\u200bHER2- Early Breast Cancer (NATALEE). https:\/\/clinicaltrials.gov\/study\/NCT03701334. Last updated September 18, 2026. Accessed September 24, 2026."},{"issue":"10","key":"10.1016\/j.annonc.2026.10.1288_bib22","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.annonc.2026.10.1288_bib23","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2- advanced breast cancer in MONALEESA-7: A phase III randomized clinical trial","volume":"28","author":"Lu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2026.10.1288_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13058-023-01701-9","article-title":"Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+\/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant","volume":"25","author":"Neven","year":"2023","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2026.10.1288_bib25","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.10.1288_bib26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.annonc.2024.10.015","article-title":"A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive\/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial","volume":"36","author":"Hortobagyi","year":"2025","journal-title":"Ann Oncol"},{"issue":"12_Supplement","key":"10.1016\/j.annonc.2026.10.1288_bib27","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-P1-11-16","article-title":"Impact of ribociclib dose reduction on efficacy in patients with hormone receptor\u2013 positive\/human epidermal growth factor receptor 2\u2013negative (HR+\/HER2\u2212) early breast cancer (EBC) in NATALEE","volume":"31","author":"Hamilton","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.annonc.2026.10.1288_bib28","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/1078-0432.CCR-24-1724","article-title":"Health-related quality of life in patients with HR+\/HER2- early breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor: Results from the NATALEE trial","volume":"31","author":"Fasching","year":"2025","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426086400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426086400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:55:09Z","timestamp":1792756509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426086400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":28,"alternative-id":["S0923753426086400"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.10.1288","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+\/HER2\u2013 early breast cancer: Six-year follow-up of the NATALEE trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.10.1288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}